Anna V. Khokhlova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anna V. Khokhlova has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Elena A. Mikhailova
N.N. Petrov National Medical Research Center of Oncology, Ministry of Health of Russia
2 shared publications - S. V. Ivanova
N.N. Petrov National Medical Research Center of Oncology, Ministry of Health of Russia; Saint-Petersburg State Pediatric Medical University, Ministry of Health of Russia
2 shared publications - Svetlana A. Kulyova
N.N. Petrov National Medical Research Center of Oncology, Ministry of Health of Russia
2 shared publications - Alexander Konstantinovich Nosov
N. N. Petrov National Medical Research Center of Oncology, Ministry of Health of Russia
1 shared publication - Anastasia A. Rukavichnikova
North-Western State Medical University Named After I.I. Mechnikov
1 shared publication - Anna S. Artemyeva
N. N. Petrov National Medical Research Center of Oncology, Ministry of Health of Russia
1 shared publication
Latest Publications
- 30 April 2026
- Published by ECO-Vector LLC (Publications) in Journal of obstetrics and women's diseases
- Vol. 75 (2) , 113-125
Bartholin’s gland cancer is a rare tumor of the vulva. Four clinical cases
The greater vestibular glands of the vagina were described in the 17th century by the Danish anatomist Caspar Bartholin the Younger. In his honor, the glands received their second name — Bartholin’s glands (BG). Obstetricians and gynecologists more often encounter retention and inflammatory lesions of the BG in their routine clinical practice. Furthermore, different types of BG epithelium can be a source of malignant tumors characterized by varying clinical courses. The following malignant BG tumors have been described in the literature: transitional cell carcinoma, neuroendocrine carcinoma, adenocarcinoma, adenosquamous carcinoma, adenoid cystic carcinoma, leiomyosarcoma, and epithelial-myoepithelial carcinoma. The diagnostic criteria for primary BG carcinoma were proposed in 1972 by Dikran L. Chamlian and Herbert B. Taylor and remain valid today: the tumor is located in the BG region and originates from cellular elements characteristic of the region; areas of clear transition from normal vulvar tissue to tumor elements are identified; there are no signs that the tumor is a metastasis from a primary tumor in another location. Malignant vulvar tumors, according to available literature, account for 3% to 5% of all vulvar carcinomas. Despite the rarity of malignant BG diseases, they constitute the majority of vulvar adenocarcinomas. Data on malignant BG tumors in the literature are presented very sparingly, mainly in the form of case reports or small series. This article describes four clinical cases of primary malignant BG tumors. All four patients were treated in the Department of Gynecologic Oncology, the N.N. Petrov National Medical Research Center of Oncology from 2019 to 2025. Two cases of HPV-associated squamous cell carcinoma, one of adenocarcinoma, and one of myoepithelial adenocarcinoma are reported. The authors present the signs and symptoms, clinical course, treatment outcomes, and recurrences of the malignant BG tumors with varying histopathologies. Malignant BG tumors can be cured with a high probability in case of early diagnosis and adequate combined treatment, including surgical removal of the tumor, radiation therapy, and polychemotherapy.
- 30 April 2026
- Published by ECO-Vector LLC (Publications) in Journal of obstetrics and women's diseases
- Vol. 75 (2) , 113-125
Bartholin’s gland cancer is a rare tumor of the vulva. Four clinical cases
The greater vestibular glands of the vagina were described in the 17th century by the Danish anatomist Caspar Bartholin the Younger. In his honor, the glands received their second name — Bartholin’s glands (BG). Obstetricians and gynecologists more often encounter retention and inflammatory lesions of the BG in their routine clinical practice. Furthermore, different types of BG epithelium can be a source of malignant tumors characterized by varying clinical courses. The following malignant BG tumors have been described in the literature: transitional cell carcinoma, neuroendocrine carcinoma, adenocarcinoma, adenosquamous carcinoma, adenoid cystic carcinoma, leiomyosarcoma, and epithelial-myoepithelial carcinoma. The diagnostic criteria for primary BG carcinoma were proposed in 1972 by Dikran L. Chamlian and Herbert B. Taylor and remain valid today: the tumor is located in the BG region and originates from cellular elements characteristic of the region; areas of clear transition from normal vulvar tissue to tumor elements are identified; there are no signs that the tumor is a metastasis from a primary tumor in another location. Malignant vulvar tumors, according to available literature, account for 3% to 5% of all vulvar carcinomas. Despite the rarity of malignant BG diseases, they constitute the majority of vulvar adenocarcinomas. Data on malignant BG tumors in the literature are presented very sparingly, mainly in the form of case reports or small series. This article describes four clinical cases of primary malignant BG tumors. All four patients were treated in the Department of Gynecologic Oncology, the N.N. Petrov National Medical Research Center of Oncology from 2019 to 2025. Two cases of HPV-associated squamous cell carcinoma, one of adenocarcinoma, and one of myoepithelial adenocarcinoma are reported. The authors present the signs and symptoms, clinical course, treatment outcomes, and recurrences of the malignant BG tumors with varying histopathologies. Malignant BG tumors can be cured with a high probability in case of early diagnosis and adequate combined treatment, including surgical removal of the tumor, radiation therapy, and polychemotherapy.
- Open Access
- 12 July 2021
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 8 (2) , 96-102
Laparoscopic kidney resection in a child with unilateral Wilms tumor
The modern Wilms tumor treatment protocols used all over the world can cure up to 90 % of children. Such successes make it possible to actively introduce risk-adapted therapy methods aimed at de-escalating the chemotherapy regimen and radiation therapy impact to the tumor. The most conservative was the stage of surgical treatment, implying the organ-depleting nature of the surgery. Nevertheless, over the past decade, a lot of experience has been accumulated with both nephron-sparing and minimally invasive interventions in patients with both bilateral and unilateral Wilms tumor.We presented the experience of laparoscopic kidney resection with intraoperative ultrasound control in a child with unilateral Wilms tumor, receiving treatment at the N.N. Petrov National Medical Research Center of Oncology.
- 12 July 2021
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 8 (2) , 96-102
Open AccessLaparoscopic kidney resection in a child with unilateral Wilms tumor
The modern Wilms tumor treatment protocols used all over the world can cure up to 90 % of children. Such successes make it possible to actively introduce risk-adapted therapy methods aimed at de-escalating the chemotherapy regimen and radiation therapy impact to the tumor. The most conservative was the stage of surgical treatment, implying the organ-depleting nature of the surgery. Nevertheless, over the past decade, a lot of experience has been accumulated with both nephron-sparing and minimally invasive interventions in patients with both bilateral and unilateral Wilms tumor.We presented the experience of laparoscopic kidney resection with intraoperative ultrasound control in a child with unilateral Wilms tumor, receiving treatment at the N.N. Petrov National Medical Research Center of Oncology.
- Open Access
- 25 September 2019
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 6 (3) , 72-76
Adverse outcome of mucormycosis in patients with non-Hodgkin’s lymphoma (clinical observation)
Over the past two decades, mucormycosis has firmly taken 3rd place among invasive mycoses after candidiasis and aspergillosis in patients with oncohematological diseases. The article presents a clinical case of disseminated mucormycosis that developed in a child with nonHodgkin’s lymphoma on the background of deep immunosuppression.
- 25 September 2019
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 6 (3) , 72-76
Open AccessAdverse outcome of mucormycosis in patients with non-Hodgkin’s lymphoma (clinical observation)
Over the past two decades, mucormycosis has firmly taken 3rd place among invasive mycoses after candidiasis and aspergillosis in patients with oncohematological diseases. The article presents a clinical case of disseminated mucormycosis that developed in a child with nonHodgkin’s lymphoma on the background of deep immunosuppression.